Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.53B P/E - EPS this Y -328.60% Ern Qtrly Grth -
Income 49.27M Forward P/E 8.03 EPS next Y 51.90% 50D Avg Chg -3.00%
Sales 380.79M PEG -0.02 EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book 4.34 EPS next 5Y 65.00% 52W High Chg -46.00%
Recommedations 2.70 Quick Ratio 5.02 Shares Outstanding 68.01M 52W Low Chg 44.00%
Insider Own 15.12% ROA 5.34% Shares Float 50.92M Beta -0.93
Inst Own 104.34% ROE 12.73% Shares Shorted/Prior 6.51M/5.09M Price 22.80
Gross Margin 59.66% Profit Margin 12.94% Avg. Volume 1,136,504 Target Price 4.25
Oper. Margin 1.78% Earnings Date May 10 Volume 815,083 Change -2.48%
About Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Amylyx Pharmaceuticals, Inc. News
04/12/24 The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
04/10/24 Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder
04/10/24 Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
04/10/24 Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
04/08/24 Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
04/06/24 Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers
04/04/24 Amylyx (AMLX) Withdraws ALS Drug, Cuts Workforce by 70%
04/04/24 ALS drug will be pulled from US market after study showed patients didn't benefit
04/04/24 UPDATE 1-Amylyx Pharma to remove ALS drug from US, Canada markets
04/04/24 Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market
04/04/24 Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
04/04/24 Amylyx to pull ALS drug from market in rare move
03/27/24 European study finds popular ALS drug ineffective
03/14/24 3 Pharma Stocks to Sell in March Before They Crash & Burn
03/14/24 Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
03/14/24 Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
03/13/24 Analysts on Wall Street Lower Ratings for These 10 Stocks
03/12/24 After surprise trial failure, ALS doctors brace for one less treatment option
03/11/24 Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%
03/11/24 Amylyx CEOs look for a path forward following major setback
AMLX Chatroom

User Image seazest Posted - 13 hours ago

$AMLX Oversold but the high volume today is a testament there is still more downside. I will wait patiently for a green day with a volume at least 2x the average. I learned a lesson long time ago , pay a bit more but never buy a falling knife. GL

User Image Zrosiez Posted - 17 hours ago

$AMLX I’ll buying more!

User Image Greenenergy33 Posted - 17 hours ago

$AMLX they bought at 20 at 40... and selling at 2, third under cash. What the fuck is wrong in this world?

User Image rao4 Posted - 20 hours ago

$AMLX I thought selling would be exhausted by now , but this high volume selling has to stop before the price can stabilize.. my only hope here tang capital taking a stake and coming up with a buyout offer (~3 dollars) . i was in AVIR when they made that offer and got out with some profit .

User Image kenny91655 Posted - 22 hours ago

$AMLX Like it better at 1.60

User Image Dboy4realz Posted - 22 hours ago

$AMLX scumbag market..no reason to drop this anymore..Nasdaq already dumped it from $20s you freakin criminals

User Image RabehS Posted - 1 day ago

$AMLX Good to get in?

User Image Greenenergy33 Posted - 1 day ago

$AMLX 50 % drop on good phase 2 trial news. Fucking rigged trashclowncasino

User Image Zrosiez Posted - 1 day ago

$AMLX When shorts attack just buy to lower your cost basis, don’t let them win! The more I buy cheap the better

User Image fishmarket Posted - 1 day ago

$SEEL $AMLX is down 87 %. Last week the CEO and the CFO bought some stocks. So even if their product failed, they are sitting on alot of cash because they managed like professional and they think they can turn this around. What about our CEO and CFO at $SEEL ?

User Image UncleStock Posted - 1 day ago

$SIGA $INVA $AMLX $VYGR suggested for $NBI US NASDAQ Biotechnology - value screen: https://zpr.io/tBVec

User Image Zrosiez Posted - 1 day ago

$AMLX Today I bought the dip at 1.88 to burn some shorts

User Image JustKen Posted - 1 day ago

$AMLX need 4 here

User Image Yassaom Posted - 2 days ago

$AMLX

User Image Zrosiez Posted - 2 days ago

$AMLX Shorts are exhausted! Now my PT is 6-8, lets keep adding

User Image thres Posted - 2 days ago

@neuroinvestor3 $clnn $amlx $bcli $amlx With all the recent ALS clinical trial set-back news, FDA approved a Phase 3b trial design for #NurOwn aka debamestrocel! We know now Nurown is the lowest hanging fruit of ALS meds and the highest on the totem pole of ALS treatments of choice. ALS patients want more than approved meds for ALS or going into clinical trials while waiting for Nurown because ALS patients know Nurown works and would be their first choice. Go Nurown!!! Nurown works!!!

User Image Zrosiez Posted - 2 days ago

$AMLX Another bad day for shorts! I’ll keep adding

User Image neuroinvestor3 Posted - 3 days ago

$CLNN Where's the publicity for the only therapy that causes remyelination of damaged neurons for MS patients? SP isn't moving because they will run out of cash in 4-5 months, no partners on-board to get them through P3 trials, and the odds of the FDA allowing ALS NDA are probably not great. Will the FDA do what they did to $BCLI? Is this another $AMLX situation? Where are the analysts? You'd think an upgrade would be in order with the recent remyelination news. Also, why aren't all the neurologists telling their friends to invest?

User Image boilerrm04 Posted - 3 days ago

@timov22 yea who knows at this point. Im still baffled $amlx is 7x more expensive

User Image dan_xdx Posted - 3 days ago

$AMLX

User Image Zrosiez Posted - 3 days ago

$AMLX Chart looks beautiful! As expected, shorts are covering with huge losses.

User Image Kursat Posted - 4 days ago

$AMLX

User Image Zrosiez Posted - 4 days ago

$AMLX I’ll keep adding more and more everyday because I believe the squeeze is near.

User Image thres Posted - 4 days ago

$BCLI $CLNN $AMLX $SEEL There is always a choice when you have the best available product. ALS patients know Nurow works. What else is there to know. When there is a will, there is a way. ALS Pationts should lobby strongly for funding for the Nurown Phase 3b clinical trials and the sooner the better. That will give them real hope and a better chance than sugar water, gold extracts, supplements or even the horrible and, I mean horribble, Radicava treatment. The other pharmas got a free pass or beaucoup cash for their clinical trials. What good did that do? From what I hear they are going nowhere really... or very small gains.

User Image deathtrack15 Posted - 5 days ago

$AMLX It's a gamble, but just picked up 1500 shares.. lets see where this takes us

User Image Zrosiez Posted - 5 days ago

$AMLX If you want to spook the shorts just buy more, that’s what I’m doing next week. I believe the stock will recover when the markets recover.

User Image 4Reel Posted - 6 days ago

$AMLX still 3 positives here, a ton of cash to 2026, big insider ownership and tutes own most of the float, and balance sheet is great

User Image Dboy4realz Posted - 6 days ago

$AMLX why did I buy this POS at $2.5 🙈

User Image Greenenergy33 Posted - 6 days ago

$AMLX shorts will spend money to their relatives funeral and medicine (who cover in time) Fuck you!

User Image black_ambition Posted - 6 days ago

@Powderedtoastman1 Why do you think $NRSN currently has a market cap only 1/5th od $AMLX, even after their ALS failure?

Analyst Ratings
Baird Neutral Apr 11, 24
HC Wainwright & Co. Buy Apr 11, 24
HC Wainwright & Co. Buy Apr 8, 24
HC Wainwright & Co. Buy Mar 12, 24
Deutsche Bank Buy Mar 11, 24
Goldman Sachs Neutral Mar 11, 24
Leerink Partners Market Perform Mar 11, 24
Baird Neutral Mar 11, 24
Evercore ISI Group In-Line Mar 8, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Klee Justin B. Co-Chief Executive O.. Co-Chief Executive Officer Jan 09 Sell 16.3281 5,841 95,372 2,836,776 01/11/24
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Jan 09 Sell 16.3281 2,716 44,347 112,035 01/11/24
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Jan 09 Sell 16.3281 5,841 95,372 2,900,470 01/11/24
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Jan 09 Sell 16.3281 2,812 45,915 205,605 01/11/24
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Nov 16 Option 1.57 63,694 100,000 2,906,311 11/20/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer May 16 Sell 27.26 32,500 885,950 55,676 05/18/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer May 16 Option 6.88 32,500 223,600 88,176 05/18/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Apr 17 Sell 30.74 49,579 1,524,058 208,417 04/19/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Apr 17 Option 3.63 49,579 179,972 257,996 04/19/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Mar 16 Sell 32.16 32,500 1,045,200 34,009 03/24/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Mar 16 Option 6.88 32,500 223,600 66,509 03/24/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Mar 16 Sell 32.14 54,627 1,755,712 199,250 03/24/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Mar 16 Option 2.53 49,578 125,432 253,877 03/24/23
Klee Justin B. Co-Chief Executive O.. Co-Chief Executive Officer Mar 16 Sell 32.16 100,000 3,216,000 2,792,617 03/20/23
MILNE GEORGE M JR Director Director Mar 16 Sell 32.15 35,000 1,125,250 862,021 03/20/23
Firestone Karen Director Director Mar 16 Buy 31.99 1,000 31,990 1,000 03/20/23
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Mar 16 Sell 32.14 100,000 3,214,000 2,792,617 03/20/23
Mazzariello Gina Chief Legal Officer Chief Legal Officer Feb 24 Sell 34.4874 3,586 123,672 37,414 02/28/23
Yeramian Patrick D Chief Medical Office.. Chief Medical Officer Jan 06 Sell 36.43 2,034 74,099 204,299 01/10/23
Cohen Joshua B Co-Chief Executive O.. Co-Chief Executive Officer Jan 06 Sell 36.43 5,968 217,414 2,892,617 01/10/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Jan 06 Sell 36.43 2,658 96,831 34,009 01/10/23
Olinger Margaret Chief Commercial Off.. Chief Commercial Officer Jan 06 Sell 36.43 2,403 87,541 214,355 01/10/23
Klee Justin B. Co-Chief Executive O.. Co-Chief Executive Officer Jan 06 Sell 36.43 5,968 217,414 2,892,617 01/10/23
FRATES JAMES M Chief Financial Offi.. Chief Financial Officer Dec 30 Option 6.88 5,000 34,400 36,667 01/04/23
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Sep 08 Sell 29.95 1,400,000 41,930,000 1,850,940 09/09/22
ALS Invest 1 B.V. 10% Owner 10% Owner Jul 06 Sell 20.97 60,609 1,270,971 5,895,280 07/08/22
Morningside Venture Investment... 10% Owner 10% Owner Jan 06 Buy 19 263,158 5,000,002 10,678,808 03/17/22
VIKING GLOBAL INVESTORS LP 10% Owner 10% Owner Jan 11 Buy 19 2,300,000 43,700,000 2,300,000 01/13/22
FONTEYNE PAUL R. Director Director Jan 06 Buy 19.00 3,947 74,993 3,947 01/10/22
Cheng Isaac Director Director Jan 06 Buy 19 6,578 124,982 6,578 01/10/22
MILNE GEORGE M JR Director Director Jan 06 Buy 19.00 26,315 499,985 221,396 01/10/22
Olinger Margaret Chief Commercial Off.. Chief Commercial Officer Jan 06 Buy 19 6,842 129,998 216,758 01/10/22